Wood Mark Form 4 January 24, 2013

## FORM 4

#### UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

Check this box

if no longer subject to Section 16. Form 4 or

Form 5 obligations may continue.

See Instruction

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF **SECURITIES** 

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934,

Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

1(b).

(Print or Type Responses)

1. Name and Address of Reporting Person \* Wood Mark

2. Issuer Name and Ticker or Trading Symbol

**BIOMARIN PHARMACEUTICAL** 

INC [BMRN]

3. Date of Earliest Transaction (Month/Day/Year)

01/22/2013

5. Relationship of Reporting Person(s) to

OMB

Number:

Expires:

response...

Estimated average

burden hours per

**OMB APPROVAL** 

10% Owner

Other (specify

3235-0287

January 31,

2005

0.5

Issuer

below)

(Check all applicable)

VP, Human Resources

(Last) (First) (Middle)

C/O BIOMARIN PHARMACEUTICAL INC., 105

(Street)

4. If Amendment, Date Original Filed(Month/Day/Year)

6. Individual or Joint/Group Filing(Check

Applicable Line)

Director

X\_ Officer (give title

\_X\_ Form filed by One Reporting Person Form filed by More than One Reporting

Person

**NOVATO, CA 94949** 

**DIGITAL DRIVE** 

(City)	(State)	(Zip) Tab	le I - Non-	Derivative	Secu	rities Acqui	red, Disposed of,	or Beneficiall	y Owned
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transactic Code (Instr. 8)	4. Securities Acquired (A) our Disposed of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
			Code V	Amount	(A) or (D)		Transaction(s) (Instr. 3 and 4)	(Instr. 4)	
Common Stock	01/22/2013(1)	01/22/2013	M	4,165	A	\$ 37.46	29,811	D	
Common Stock	01/22/2013(1)	01/22/2013	M	40,000	A	\$ 38.59	69,811	D	
Common Stock	01/22/2013(1)	01/22/2013	M	939	A	\$ 14.39	70,750	D	
Common Stock	01/22/2013(1)	01/22/2013	M	812	A	\$ 26.49	71,562	D	
	01/22/2013(1)	01/22/2013	M	833	A	\$ 21.51	72,395	D	

Common Stock

Common Stock	01/22/2013(1)	01/22/2013	S	2,584	D	\$ 54.8091 (2)	69,811	D
Common Stock	01/22/2013(1)	01/22/2013	S	44,165	D	\$ 55	25,646	D

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1474

(9-02)

 $\label{thm:convergence} \begin{tabular}{ll} Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned \\ (e.g., puts, calls, warrants, options, convertible securities) \end{tabular}$ 

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transacti Code (Instr. 8)	5. Number of orDerivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisab Expiration Date (Month/Day/Year	7. Title and Amount of Underlying Securities (Instr. 3 and 4)		
				Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amour or Number of Shar
Stock Option (right to buy) Common Stock	\$ 38.59	01/22/2013(1)	01/22/2013	М	40,000	11/22/2008(3)	05/21/2018	Common Stock	40,00
Stock Option (right to buy) Common Stock	\$ 37.46	01/22/2013(1)	01/22/2013	М	4,165	11/08/2012(4)	05/08/2022	Common Stock	4,16
Stock Option (right to buy)	\$ 26.49	01/22/2013(1)	01/22/2013	M	812	11/12/2011(5)	05/11/2021	Common Stock	812
Stock Option (right to buy)	\$ 14.39	01/22/2013(1)	01/22/2013	M	939	11/12/2009 <u>(6)</u>	05/11/2019	Common Stock	939

Common Stock

Stock Option

(right to buy)

\$ 21.51 01/22/2013(1)

01/22/2013

M

833

11/12/2010(7) 05/11/2020

Common

833

Stock

Common Stock

# **Reporting Owners**

Reporting Owner Name / Address

Relationships

Director 10% Owner Officer

Other

Wood Mark

C/O BIOMARIN PHARMACEUTICAL INC. 105 DIGITAL DRIVE

NOVATO, CA 94949

VP, Human Resources

## **Signatures**

/s/ Laura Woodhead, Attorney-in-Fact

01/24/2013

\*\*Signature of Reporting Person

Date

## **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Transaction made pursuant to a Rule 10b5-1 plan executed on August 13, 2012.
- The price in Column 4 is a weighted average price. The prices actually received ranged from \$54.27 to \$55.33. The reporting person will
- (2) provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
- (3) Original option grant vests 6/48th on November 22, 2008 and 1/48th each on the 22nd of each month thereafter.
- (4) Original option grant vests 6/48th on November 8, 2012 and 1/48th each on the 8th of each month thereafter.
- (5) Original option grant vests 6/48th on November 12, 2011 and 1/48th each on the 12th of each month thereafter.
- (6) Original option grant vests 6/48th on November 12, 2009 and 1/48th each on the 12th of each month thereafter.
- (7) Original option grant vests 6/48th on November 12, 2010 and 1/48th each on the 12th of each month thereafter. Remarks:

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

Reporting Owners 3